This Oxfordshire firm, led by chief executive Eliot Forster, 51, develops drugs that harness the body’s immune system to fight cancer, infectious diseases and autoimmune diseases. In 2015 it raised £205m from investors including Woodford Investment Management and Malin. It also set up a subsidiary in America. The company’s partnerships with drug giants such as Glaxo Smith Kline and Astra Zeneca brought revenue of £16.5m in 2016, when it also made a large loss. It is expanding its Oxfordshire laboratory by 53,000 sq ft.
This profile reflects the company at time of publication and does not reflect any changes that may have subsequently occurred. Fast Track and its sponsors do not endorse, guarantee or recommend investment in any of the companies.